- Innovative Medicines Initiative for Diabetes:
Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in Diabetes
News, Events, Presentations and PublicationsFlyer: IMI - diabetes project, October 01, 2012 more…
Press Release: IMIDIA funding by JDRF, May 03, 2012 more…
IMI Stakeholder Forum, June 14&15, 2010 more…
IMIDIA Launch Press Release, June 14, 2010 more…
The project “Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)” has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115005, resources of which are composed of financial contribution from European Union`s Seventh Framework programme (FP7/2007-2013) and EFPIA companies´ in kind contribution.
The website reflects only the author´s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
IMIDIA Participantsclick here for more information
Leading European experts from fourteen academic research institutions, eight pharmaceutical industry research organizations and one biotech company in the area of pancreatic beta-cell research officially launched the IMIDIA project on February 1, 2010
The IMIDIA proposal has been published in the first call for proposal of the Innovative Medicines Initiative (IMI), which is part of the EU Seventh Framework programme (FP7).
IMIDIA, supported by the EU IMI Joint Undertaking of public and private partners, is laying the foundation for a paradigm shift in the treatment of Diabetes:
- from symptomatic treatment to pancreatic beta-cell focused cure of this emerging pandemic disease
The close cooperation of academic teams, pharmaceutical companies and Small to Medium Enterprises (SMEs) in the IMIDIA project will provide a unique platform of expertise of an EU-supported public-private partnership to persistently improve industrial competitiveness and Public Health in Europe.